Advertisement

Topics

Companies Related to "starts Phase Tremfya plaque type psoriasis" [Most Relevant Company Matches] RSS

13:10 EST 13th December 2018 | BioPortfolio

Here are the most relevant search results for "starts Phase Tremfya plaque type psoriasis" found in our extensive corporate database of over 50,000 company records.

Showing "starts Phase Tremfya plaque type psoriasis" Companies 1–25 of 1,400+

Relevant

National Psoriasis Foundation

The National Psoriasis Foundation is the world's largest nonprofit organization serving people with psoriasis and psoriatic arthritis. Our mission is to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education. For more information, call the Psoriasis Foundation, headquartered in Portland, Ore., at 800.723.9166, or visit ...


International Federation of Psoriasis Associations

The International Federation of Psoriasis Associations (IFPA) is a non profit umbrella organization made up of psoriasis associations from around the world. Today IFPA has 40 member associations. IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the l...

Avid Radiopharmaceuticals, Inc.

Avid Radiopharmaceuticals is a leader in the development of molecular imaging products with the potential for earlier and more effective detection, diagnosis and monitoring of major chronic human diseases. Based in Philadelphia, PA, the company’s lead program is a molecular imaging agent for amyloid plaque that could lead to earlier detection and bett...


International Psoriasis Council

The International Psoriasis Council (IPC) is a global non-profit organization dedicated to advancing psoriasis research and treatment by providing a forum for education, collaboration, and innovation among physicians, researchers and other professionals interested in psoriasis.

AMEVIVE

AMEVIVE is the first biologic approved by the FDA for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AMEVIVE is a prescription medication that is injected by your doctor (15 mg IM, into the muscle) once a week for a total of 12 doses.

Psoriasis - Matters

www.psoriasis-matters.co.uk is a specialist psoriasis site brought to you by the same team that developed allergymatters.com . www.psoriasis-matters.co.uk will carry the best range of psoriasis UV UVB Light Therapy units and the most suitable creams, ointments and shampoos available in the market. www.psoriasis-matters.co.uk will provide expert reviews and unbiased psoriasis product ratings to un...

Plaxgen, Inc.

Privately-held Plaxgen is developing diagnostics in atherosclerosis, Alzheimer’s disease, and other plaque-related diseases, using its proprietary Plaque Array technology.

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Foxhollow Technologies

An estimated 12 million people in the U.S. alone have peripheral arterial disease (PAD). At least 40% of them also suffer from coronary artery disease (CAD). FoxHollow recently launched the SilverHawk® Plaque Excision System, a device that removes the plaque that commonly blocks arteries and interrupts blood flow. Unlike stenting and other methods of opening the artery, the SilverHawk removes the...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and are developing scientifically and clinically validated over the counter and prescription products that utilize TFS’ cultivated, sustainable, pharmaceutical-grade East Indian S...

DARA BioSciences, Inc.

DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND’s (Investigationa...

Zelos Therapeutics Inc.

Zelos Therapeutics is an emerging private biopharmaceutical development company that is commercializing breakthrough discoveries in parathyroid hormone (PTH) research. The company is developing medications for the treatment of osteoporosis, psoriasis and for enhancing engraftment following stem cell transplantation. During 2005, Zelos Therapeutics experienced a number of significant milestones. Ke...

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in...

Ra Medical Systems, Inc.

Ra Medical Systems was founded in 2002 and is a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of dermatologic and vascular diseases. DABRA, launched in 2017, is used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular dise...

Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic liver cance...

iResearch

iResearch is a specialist Clinical Research Resourcing organisation providing a tailored management outsourcing service for the provision of interim medical, clinical and technical staff. The expertise of iResearch to provide Phase I services has been built on the delivery of a highly professional Phase I Bank Resource to three top ranking Pharmaceutical Companies over the last 3 years. We now of...

TolerRx, Inc.

We are a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat patients with immunological diseases. TolerRx has a development pipeline which includes two humanized antibodies that are in clinical trials for new-onset type 1 diabetes, psoriasis, and cutaneous lupus erythematosus. We also have ongoing research and development programs foc...

Avontec GmbH

AVONTEC GmbH is a phase II biopharmaceutical company engaged in the development of a novel class of anti-inflammatory drugs that are based on double-stranded DNA oligonucleotides acting as decoys (decoy ODNs) for transcription factors. AVONTECs most advanced clinical development programs focus on the indications asthma (AVT-01) and psoriasis (AVT-02).

POXEL S.A.

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, ...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver....

Neuromed

Neuromed is a biopharmaceutical company developing new and improved pain therapies. Lead drug candidate, OROS Hydromorphone®, in Phase 3 clinical development, is an extended release formulation of hydromorphone. In collaboration with Merck, Neuromed is also researching compounds designed to block the N-type calcium channel, a target linked to pain signal transmission. Separately, Neuromed is deve...

Neuromed Pharmaceuticals

Neuromed is a biopharmaceutical company developing new and improved pain therapies. Lead drug candidate, OROS Hydromorphone®, in Phase 3 clinical development, is an extended release formulation of hydromorphone. In collaboration with Merck, Neuromed is also researching compounds designed to block the N-type calcium channel, a target linked to pain signal transmission. Separately, Neuromed is deve...

VBL Therapeutics

VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents and VB-201 is the lead candidate from this program, which has entered Phase 2 clinical development in patients with psor...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, is an oral histamine H4 receptor antagonist, currently in two Phase 2a studies: the first in atopic dermatitis is fully recruited and will read out in Q2 2016; and the second has ...

Meyer Pharmaceuticals, LLC

Meyer Pharmaceuticals, LLC is a biopharmaceutical company dedicated to researching and developing innovative therapies for the treatment of inflammatory diseases and related disorders. Our therapeutic targets (rheumatoid arthritis, osteoarthritis, severe plaque psoriasis, inflammatory bowel disease, and sepsis) afflict over 60 million people worldwide. Our business strategy is to use our state-of...


More From BioPortfolio on "starts Phase Tremfya plaque type psoriasis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks